molybdenum has been researched along with navitoclax in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chandel, NS; Diebold, LP; Glasauer, A; Mazar, AP; Sena, LA | 1 |
| Briehl, MM; Hart, MR; Lee, K; Mazar, AP; Tome, ME | 1 |
2 other study(ies) available for molybdenum and navitoclax
| Article | Year |
|---|---|
Targeting SOD1 reduces experimental non–small-cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Hydrogen Peroxide; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molybdenum; Myeloid Cell Leukemia Sequence 1 Protein; Sulfonamides; Superoxide Dismutase; Superoxide Dismutase-1; Tumor Burden; Tumor Suppressor Protein p53 | 2014 |
The copper chelator ATN-224 induces caspase-independent cell death in diffuse large B cell lymphoma.
Topics: Aniline Compounds; Apoptosis; Apoptosis Inducing Factor; Caspases; Cell Line, Tumor; Chelating Agents; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; Mitochondria; Molybdenum; Sulfonamides | 2014 |